FindTrial
Sign In

A Prospective Observational Analytical Study On Diagnostic Utility of Cancer Ratio and Cancer Ratio Plus in Differentiating Malignant from Non-Malignant Pleural Effusion Among Patients with Pleural Effusion at AVBRH Sawangi Wardha

TO STUDY THE UTILITY OF CANCER RATIO AND CANCER RATIO PLUS IN DIFFERENTIATING MALIGNANT PLEURAL EFFUSION FROM NON MALIGNANT PLEURAL EFFUSION AT AVBRH , SAWANGI , WARDHA - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093292
Enrollment
45
Registered
2025-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J99- Diseases of the respiratory system

Interventions

Intervention1: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

Datta Meghe Institute Of Higher Education and Rearch
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All Patients Both Male And Female Presenting With Exudative Pleural Effusions At AVBRH,DMIHER,Sawangi,WARDHA [Age More Than 18 Years]

Exclusion criteria

Exclusion criteria: Participants Who Are Not Willing To Participate

Design outcomes

Primary

MeasureTime frame
To Find a Marker and To Confirm Its Diagnostic Utility For Differentiating MPE from Nonmalignant EffusionsTimepoint: At Day 0 (thoracentesis ? sample collection & calculation) with confirmation by Day 30—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Babaji Ghewade

Datta Meghe Institution Of Higher Education And Research

Crownbabaji@gmail.com9822342770

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026